Lila Levinson, PhD,  Science Writer—

People from underrepresented racial and ethnic groups who have hereditary angioedema (HAE) continue facing barriers to diagnosis and effective care, according to a recent study. These patients reported having trouble getting adequate care before their diagnosis, and though most were satisfied with the treatment they received afterward, many…

Kaken Pharmaceutical obtained the rights to commercialize sebetralstat, an on-demand treatment for hereditary angioedema (HAE), in Japan under a licensing agreement with the HAE treatment’s developer, Kalvista Pharmaceuticals. Under the terms of the agreement, Kalvista will be eligible to receive an upfront payment of $11 million,…